Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 26, 2013
Event Date: December 24, 2013
Context: The Company entered into definitive agreements to conduct a registered direct offering of common stock.
Key Financial Metrics
This filing reports on a specific capital raising transaction rather than periodic financial performance. Key transaction metrics include:
- Shares to be Sold: 1,580,000 shares of common stock.
- Offering Price: $10.00 per share.
- Gross Proceeds: Approximately $15,800,000.
- Placement Agent Fees: Approximately $790,000 (cash compensation) plus expense reimbursement.
- Estimated Net Proceeds: Approximately $14,890,000 after deducting fees and estimated offering expenses.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the execution of a Placement Agency Agreement with Aegis Capital Corp. and a Securities Purchase Agreement with two institutional investors. This represents a new equity financing event expected to increase the Company's cash position upon closing.
Guidance, Outlook, and Risks
- Expected Closing: The Offering is expected to close on or about December 31, 2013.
- Contingencies: Closing is subject to the satisfaction of customary conditions. If conditions are not met, the Offering may not close.
- Forward-Looking Statements: The Company explicitly warns that statements regarding the closing date and proceeds are not guaranteed and are subject to risks beyond the Company's control.
- Regulatory Status: Shares will be issued pursuant to a prospectus supplement filed under an effective shelf registration statement (Form S-3).
Investor Verification Checklist
- Verify the actual closing date of the Offering (expected Dec 31, 2013) and confirm if all customary conditions were satisfied.
- Confirm the final number of shares sold and the exact net proceeds received after all expenses.
- Review the Prospectus Supplement (filed with the SEC) for detailed risk factors and use of proceeds.
- Check subsequent filings for any updates on the Company's liquidity position post-offering.